Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)
Christoph Rochlitz, Khalil Zaman, Sun Young Rha(Yonsei University), Roger von Moos(Kantonsspital Graubünden), Christian Spirig(Kantonsspital St. Gallen), B. Cliffe(Swiss Group For Clinical Cancer Research), Michael Mayer(Swiss Group For Clinical Cancer Research), M. Mannhart-Harms(Hirslanden Andreasklinik Cham Zug), Stefanie Lerch(Swiss Group For Clinical Cancer Research), Jens Huober(University of St.Gallen), Thomas Suter(University of Bern), Richard Herrmann(New York State Department of Health), Monika Bühlmann(University Hospital of Bern), Andreas Müller(Kantonsspital Winterthur), A. Schönenberger(Kantonsspital Aarau), Thomas Ruhstaller(University Hospital Bonn), MK Fehr(University Hospital Zurich), Daniel Rauch(Washington University in St. Louis)
Cited by 26
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k